Keros Therapeutics KROS 深 沪
等待开盘 09-29 09:30:00 美东时间
11.28
-0.340
-2.93%
华盛通- 最 高11.41
- 今 开11.33
- 成交量 20.86万股
- 最 低 10.925
- 昨 收 11.62
- 总市值 2.24亿
- 52周最高 22.55
- 市盈率 静 4.91
- 换手率 1.05%
- 52周最低 9.69
- 委 比 -94.24%
- 总股本 1982.72万
- 历史最高 88.80
- 量 比 1.08
- 振 幅 4.17%
- 历史最低 9.12
- 每 手 1
- 风险率 3.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy
Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") fami...
09-28 20:03
Keros Therapeutics launches $5M share buyback after $20M milestone
Keros Therapeutics (KROS) announced on Tuesday that its board approved a $5M share repurchase program for its common stock. The buyback follows a $20M development milestone payment from Takeda Pharmac...
09-09 04:09
Keros Therapeutics Reveals $5M Share Repurchase Authorization
Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-bet...
09-09 04:02
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Keros Therapeutics announced a $5 million share repurchase program after receiving a $20 million milestone payment from Takeda for elritercept, following the first patient dosing in the ELRiSE MDS trial. The program allows repurchases in the open market, subject to market conditions and regulations. Keros focuses on TGF-ß-related therapies, with rinvatercept for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, and elritercept for cy...
09-08 20:01
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of $(0.76) per share from the same period last year.
08-04 04:12
Keros Therapeutics Reports Second Quarter 2026 Financial Results
Keros Therapeutics reported a net loss of $28.7 million in Q2 2026, down from $30.7 million in Q2 2025, due to reduced R&D expenses and restructuring. The company initiated a Phase 2 trial for rinvatercept in Duchenne muscular dystrophy, with positive Phase 1 results showing increased muscle mass and bone density. Cash reserves stood at $257.6 million, expected to fund operations into 2028. Keros remains focused on advancing its TGF-β signaling t...
08-03 20:01
Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial
ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or intermediate risk myelodysplastic syndromes ("MDS"). "We are delighted by the continued progress of the elrite...
07-31 04:04
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
Keros Therapeutics will receive a $20 million milestone payment from Takeda following the dosing of the first patient in the Phase 3 ELRiSE MDS trial, which compares elritercept to epoetin alfa for treating anemia in MDS patients. Keros has already received a $200 million upfront payment under the global license agreement and is eligible for up to $1.1 billion in additional milestones. The company plans to distribute 25% of the net proceeds to it...
07-30 20:01
Keros Therapeutics CFO Keith Regnante Resigns, Effective Aug. 3; VP Finance Annita Tanini Named Interim Principal Financial Officer
https://www.sec.gov/ix?doc=/Archives/edgar/data/1664710/000166471026000038/kros-20260717.htm
07-23 04:49
